Cargando…

The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis

BACKGROUND: The treatment of solid malignant tumors using immune checkpoint inhibitors (ICIs) combined with antiangiogenic drugs, has gradually become an active field of clinical research. However, the results are inconsistent. Therefore, we designed this meta-analysis to evaluate the efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Qian, Li, Jiayi, Zhang, Chi, Tang, Sheng, Ren, Qinglan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798721/ https://www.ncbi.nlm.nih.gov/pubmed/35117287 http://dx.doi.org/10.21037/tcr-20-1975

Ejemplares similares

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis
por: He, Qian, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
por: Xue, Liting, et al.
Publicado: (2021)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019)

Hypothyroidism induced by immune checkpoint inhibitors combined with antiangiogenic agents is associated with higher body mass index
por: Wang, Xinyue, et al.
Publicado: (2023)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
por: Feng, Jin-Kai, et al.
Publicado: (2022)

Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy
por: Yonucu, Sirin, et al.
Publicado: (2017)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Liao, Juan-Yan, et al.
Publicado: (2021)

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis
por: Li, Jiaqi, et al.
Publicado: (2022)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
por: Yao, Junlin, et al.
Publicado: (2022)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
por: Chen, Jingjie, et al.
Publicado: (2020)

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety
por: Welker, Martin-Walter, et al.
Publicado: (2013)

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
por: Liu, Xiangxing, et al.
Publicado: (2022)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
por: Pan, Xian, et al.
Publicado: (2023)

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
por: Peng, Min, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2023)

Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
por: Adamcic, Una, et al.
Publicado: (2012)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

A case series on the efficacy and safety of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer
por: Song, Hualin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vtd12f3ipf9vfkt1knpbd4ucft